Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study

David M. MacDonald; Gary Collins; Chris H. Wendt; Julian Wolfson; Russell P. Tracy; Frank Rhame; Steven Deeks; Stacey A. Rizza; Zelalem Temesgen; Caryn Morse; Angelike P. Liappis; Irini Sereti; Jason V. Baker; Ken M. Kunisaki

doi:10.1089/aid.2020.0285

Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study

David M. MacDonald, Gary Collins, Chris H. Wendt, Julian Wolfson, Russell P. Tracy, Frank Rhame, Steven Deeks, Stacey A. Rizza, Zelalem Temesgen, Caryn Morse, Angelike P. Liappis, Irini Sereti, Jason V. Baker, Ken M. Kunisaki

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo (p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.

Original language	English (US)
Pages (from-to)	127-130
Number of pages	4
Journal	AIDS Research and Human Retroviruses
Volume	38
Issue number	2
DOIs	https://doi.org/10.1089/aid.2020.0285
State	Published - Feb 2022

Bibliographical note

Funding Information:
This study was funded by a grant from the NIH National Institute on Aging (NIA/NIH: R01 AG045032). Study drug was provided by Merck Pharmaceuticals. D.M.M. was supported by the University of Minnesota T32 Training in Lung Science training grant (NHLBI: T32 HL007741). I.S. was supported by the intramural research program of NIAID/ NIH. K.M.K. was supported by resources and the use of facilities at the Minneapolis VA Health Care System (Minneapolis, MN).

Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.

Keywords

HIV
angiotensin receptor antagonists
biomarkers
lung diseases
pulmonary surfactant-Associated protein D
uteroglobulin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1089/aid.2020.0285

Find It

Find It at U of M Libraries

Cite this

MacDonald, D. M., Collins, G., Wendt, C. H., Wolfson, J., Tracy, R. P., Rhame, F., Deeks, S., Rizza, S. A., Temesgen, Z., Morse, C., Liappis, A. P., Sereti, I., Baker, J. V., & Kunisaki, K. M. (2022). Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study. AIDS Research and Human Retroviruses, 38(2), 127-130. https://doi.org/10.1089/aid.2020.0285

MacDonald, DM , Collins, G , Wendt, CH , Wolfson, J, Tracy, RP, Rhame, F, Deeks, S, Rizza, SA, Temesgen, Z, Morse, C, Liappis, AP, Sereti, I, Baker, JV & Kunisaki, KM 2022, 'Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study', AIDS Research and Human Retroviruses, vol. 38, no. 2, pp. 127-130. https://doi.org/10.1089/aid.2020.0285

@article{ca0f00d0c51a43d184dd0098ab631465,

title = "Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study",

abstract = "HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo (p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.",

keywords = "HIV, angiotensin receptor antagonists, biomarkers, lung diseases, pulmonary surfactant-Associated protein D, uteroglobulin",

author = "MacDonald, {David M.} and Gary Collins and Wendt, {Chris H.} and Julian Wolfson and Tracy, {Russell P.} and Frank Rhame and Steven Deeks and Rizza, {Stacey A.} and Zelalem Temesgen and Caryn Morse and Liappis, {Angelike P.} and Irini Sereti and Baker, {Jason V.} and Kunisaki, {Ken M.}",

note = "Funding Information: This study was funded by a grant from the NIH National Institute on Aging (NIA/NIH: R01 AG045032). Study drug was provided by Merck Pharmaceuticals. D.M.M. was supported by the University of Minnesota T32 Training in Lung Science training grant (NHLBI: T32 HL007741). I.S. was supported by the intramural research program of NIAID/ NIH. K.M.K. was supported by resources and the use of facilities at the Minneapolis VA Health Care System (Minneapolis, MN). Publisher Copyright: {\textcopyright} Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.",

year = "2022",

month = feb,

doi = "10.1089/aid.2020.0285",

language = "English (US)",

volume = "38",

pages = "127--130",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Short Communication

T2 - A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study

AU - MacDonald, David M.

AU - Collins, Gary

AU - Wendt, Chris H.

AU - Wolfson, Julian

AU - Tracy, Russell P.

AU - Rhame, Frank

AU - Deeks, Steven

AU - Rizza, Stacey A.

AU - Temesgen, Zelalem

AU - Morse, Caryn

AU - Liappis, Angelike P.

AU - Sereti, Irini

AU - Baker, Jason V.

AU - Kunisaki, Ken M.

N1 - Funding Information: This study was funded by a grant from the NIH National Institute on Aging (NIA/NIH: R01 AG045032). Study drug was provided by Merck Pharmaceuticals. D.M.M. was supported by the University of Minnesota T32 Training in Lung Science training grant (NHLBI: T32 HL007741). I.S. was supported by the intramural research program of NIAID/ NIH. K.M.K. was supported by resources and the use of facilities at the Minneapolis VA Health Care System (Minneapolis, MN). Publisher Copyright: © Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.

PY - 2022/2

Y1 - 2022/2

N2 - HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo (p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.

AB - HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo (p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.

KW - HIV

KW - angiotensin receptor antagonists

KW - biomarkers

KW - lung diseases

KW - pulmonary surfactant-Associated protein D

KW - uteroglobulin

UR - http://www.scopus.com/inward/record.url?scp=85124432796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124432796&partnerID=8YFLogxK

U2 - 10.1089/aid.2020.0285

DO - 10.1089/aid.2020.0285

M3 - Article

C2 - 33749317

AN - SCOPUS:85124432796

SN - 0889-2229

VL - 38

SP - 127

EP - 130

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - 2

ER -

Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this